Literature DB >> 18097046

Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.

Patricia M Petritus1, James M Burns.   

Abstract

Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection. Using this merozoite surface protein-based vaccine model, we investigated vaccine- and infection-induced immune responses that contribute to protection. Analysis of prechallenge sera from rPyMSP-8-immunized C57BL/6 and BALB/c mice revealed high and comparable levels of Ag-specific IgG, but differences in isotype profile and specificity for conformational epitopes were noted. As both strains of mice were similarly protected against P. yoelii, we could not correlate vaccine-induced responses with protection. However, passive immunization studies suggested that protection resulted from differing immune responses. Studies with cytokine-deficient mice showed that protection was induced by immunization of C57BL/6 mice only when IL-4 and IFN-gamma were both present. In BALB/c mice, the absence of either IL-4 or IFN-gamma led to predictable shifts in the IgG isotype profile but did not reduce the magnitude of the Ab response induced by rPyMSP-8 immunization. Immunized IL-4-/- BALB/c mice were solidly protected against P. yoelii. To our surprise, immunized IFN-gamma-/- BALB/c mice initially controlled parasite growth but eventually succumbed to infection. Analysis of cytokine production revealed that P. yoelii infection induced two distinct peaks of IFN-gamma that correlated with periods of controlled parasite growth in intact, rPyMSP-8-immunized BALB/c mice. Maximal parasite growth occurred during a period of sustained TGF-beta production. Combined, the data indicate that induction of protective responses by merozoite surface protein-based vaccines depends on IL-4 and IFN-gamma-dependent pathways and that vaccine efficacy is significantly influenced by host responses elicited upon infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097046     DOI: 10.4049/jimmunol.180.1.444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor attenuate blood-stage malaria.

Authors:  Swati Thorat; Thomas M Daly; Lawrence W Bergman; James M Burns
Journal:  Infect Immun       Date:  2010-09-13       Impact factor: 3.441

2.  Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice.

Authors:  Shigeto Yoshida; Hitomi Araki; Takashi Yokomine
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

3.  MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.

Authors:  Susanna J Dunachie; Tamara Berthoud; Sheila M Keating; Adrian V S Hill; Helen A Fletcher
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

4.  Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1).

Authors:  Jia Zhao; Shu Deng; Jiayuan Liang; Yaming Cao; Jun Liu; Feng Du; Hong Shang; Liwang Cui; Enjie Luo
Journal:  Hum Vaccin Immunother       Date:  2013-01-28       Impact factor: 3.452

5.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

6.  Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.

Authors:  Michelle M Lynch; Amy Cernetich-Ott; William P Weidanz; James M Burns
Journal:  Clin Vaccine Immunol       Date:  2008-12-30

7.  Secreted antibody is required for immunity to Plasmodium berghei.

Authors:  Julia K Nunes; Michael N Starnbach; Dyann F Wirth
Journal:  Infect Immun       Date:  2008-11-10       Impact factor: 3.441

8.  Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model.

Authors:  Patricia Ferrer; Abhai K Tripathi; Martha A Clark; Carla Cerami Hand; Hugh Young Rienhoff; David J Sullivan
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

9.  IL-27 receptor signaling regulates memory CD4+ T cell populations and suppresses rapid inflammatory responses during secondary malaria infection.

Authors:  Emily Gwyer Findlay; Ana Villegas-Mendez; Noelle O'Regan; J Brian de Souza; Lisa-Marie Grady; Christiaan J Saris; Eleanor M Riley; Kevin N Couper
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

10.  Augmented particle trapping and attenuated inflammation in the liver by protective vaccination against Plasmodium chabaudi malaria.

Authors:  Jürgen Krücken; Denis Delić; Heike Pauen; Anna Wojtalla; Manal El-Khadragy; Mohamed A Dkhil; Horst Mossmann; Frank Wunderlich
Journal:  Malar J       Date:  2009-04-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.